ACTRN12612000576820已完成1 期
The pharmacokinetics, tolerability and safety of vessel dilator (VSDL) peptide following subcutaneous infusion to steady state in patients with stable congestive heart failure and moderate renal impairment.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.A history of stable, symptomatic CHF, with a left ventricular ejection fraction (LVEF) of less than or equal to 45% measured with transthoracic echocardiogram (TTE) or gated blood pool scan, performed within 90 days prior to screening
- •2.Signed Informed Consent
- •3.Aged 18 years or older
- •4.Non-pregnant females as evidenced by serum pregnancy test at screening and negative urine pregnancy test pre dose at Day 1 (for women of child bearing potential only). Women of child bearing potential must agree to use a medically acceptable method of contraception (as determined by the Investigator) for the entire study duration. Females of non child bearing potential are defined as having amenorrhea for at least 2 years prior to study entry or have been surgically sterilized
- •5.Brain Natriuretic Peptide (BNP) greater than or equal to 100 pg/mL
- •6.GFR greater than or equal to 25 mL/min and less than 70 mL/min as calculated by Cockroft Gault formula
排除标准
- •1.Evidence of myocardial infarction (MI) or high risk acute coronary syndrome within past 6 weeks, as evidenced by ST elevation by a 12-lead ECG or by creatine phosphokinase muscle-brain isoenzyme (CK-MB) greater than or equal to 3 times upper limit of normal (as defined by Institute of Medical and Veterinary Science (IMVS)) or elevation of troponin T >0.1
- •2.Evidence of Acute MI (ST elevation and/or elevation of Troponin-T), as determined by a 12-lead ECG and plasma troponin levels
- •3.Hypotension (Systolic Blood Pressure (SBP)<90 mmHg), cardiogenic shock, volume depletion or any other clinical condition that would contraindicate administration of an agent with potent vasodilatory effects
- •4.Persistent, uncontrolled hypertension (SBP>180 mm Hg)
- •5.Congenital heart defects
- •6.Cardiac surgery within past 4 weeks
- •7.Severe valvular heart disease: aortic stenosis (AS), hypertrophic obstructive cardiomyopathy (HOCM), aortic incompetence (AI) or mitral regurgitation (MR)
- •8.Alteration to dose/type/frequency of background therapeutic doses of a beta-blocker, ACE-I or ARB within the previous six weeks.
- •9.Alteration to dose/type/frequency of background therapeutic doses of a diuretic and/or aldosterone receptor inhibitor (e.g. spironolactone) within the previous six weeks.
- •10.History of cerebrovascular accident within past 4 weeks
- •11.Acute or chronic active infection, including pneumonia and urinary tract infection
- •12.Significant renal impairment as determined by a GFR of <25 ml/min as calculated with Cockroft Gault formula. All participants will be required to demonstrate a stable GFR pre-dose on Day 1 to ensure that GFR has not fallen below the protocol specified criteria for ongoing enrolment into the study.
- •13.Presence of hepatic impairment (defined as ALP, ALT, AST, GGT, Bilirubin >2x ULN) and/or the presence of ascites
- •14.Other clinically significant findings on any of the screening laboratory tests, as determined by the Investigator, including but not limited to: hyponatremia, hyperkalaemia, acidosis, anaemia (defined as Hb <9g/dL)
- •15.Diagnosis of syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH), Addison’s disease or renal salt wasting disease
- •16.Receipt of Investigational Drug within 30 days of screening or current enrollment in a clinical trial
- •17.History of clinically significant drug or alcohol abuse within the past 12 months – as judged by the Investigator
- •18.History of renal or cardiac transplantation
- •19.Insufficient venous access
- •20.History of current malignancy or malignancy requiring chemotherapy/radiotherapy within 2 years of enrolment (including any current or past history of prostatic malignancy)
- •21.History of nephrotic syndrome or clinically significant proteinuria (>1g/24hr)
- •22.Known history of infection with Hepatitis C, B or Human Immunodeficiency Virus
- •23.Use of NSAIDS within 24 hours, or five half-lives, whichever is longer, of start of infusion
- •24.History of chronic migraine (defined as >15 episodes per month)
- •25.Inability to conform to the conditions of the protocol.
研究者
相似试验
已完成
1 期
The pharmacokinetics and clinical tolerability of ascending single doses of an oral tablet formulation of BNC210 in healthy male volunteersAnxiety disordersTrauma-and stressor-related disordersMental Health - AnxietyMental Health - Other mental health disordersACTRN12619001180101Bionomics Limited5
已完成
1 期
The pharmacokinetics and clinical tolerability of ascending single doses of BNC210, an anxiolytic compound, in healthy volunteersACTRN12609000577213Bionomics Limited4
尚未招募
不适用
Clofazimine and moxifloxacin PK, safety, and AccepTAbiLitY for paediatric TB treatment (CATALYST)TuberculosisPACTR202012756409365Stellenbosch University36
进行中（未招募）
不适用
Pharmacokinetics, pharmacodynamics and safety of a new Leuprolide acetate 22.5 mg depot formulation, when given as palliative treatment to prostate cancer patientsMedDRA version: 8.1Level: LLTClassification code 10007113Term: Cancer of prostateProstate cancerEUCTR2006-005964-24-GBItalfarmaco S.p.A.20
尚未招募
2 期
IVERSAL2: Pharmacokinetics safety and acceptability of DRV/r for children living with HIVHIV/AIDSPACTR202405769820746Fondazione Penta ETS50